Uniphar records strong profit growth of over 6% driven by pharma division

Uniphar chief executive Ger Rabbette said the group remains confident of achieving their target of €200m earnings before interest, taxes, depreciation, and amortisation by 2028.

Healthcare services firm Uniphar has seen its revenue and profit increase over the first six months of this year driven by strong growth in its pharma division.

In the six-month period, it generated revenue of nearly €1.49bn - up 8.6% compared to the same period in 2024. Its gross profit stood at €219.65m, an increase of 6.3%.

Uniphar chief executive Ger Rabbette said the group remains confident of achieving their target of €200m earnings before interest, taxes, depreciation, and amortisation by 2028.

“Our uncompromising focus on solving our healthcare clients’ challenges, together with our strategic investment programme, further enhances our capability to deliver strong organic growth into the future,” he said.

Its earnings before interest, taxes, depreciation, and amortisation stood at €57.5m for the January to June period - up 2.9%.

For the full year of 2025, the company expects organic gross profit growth across all divisions to be in line with medium-term targets.

The company said it has experienced growth across all three of its divisions, pharma, medtech, as well as supply chain and retail.

The group’s pharma division saw a 17.6% growth in organic gross profit while its medtech division saw a 7.5% growth which it said was achieved “through consistent growth in core markets, portfolio expansion and expanding our geographic reach”.

Its supply chain and retail division saw 3.0% organic gross profit growth.

Uniphar is headquartered in Dublin and provides services to more than 200 multinational pharmaceutical and medical technology manufacturers.